Publications

Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA et al..  2004.  Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.. Cancer Res. 64(24):9209-16.

Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, Giacherio D, Ghosh D, Sanda MG, Rubin MA, Chinnaiyan AM.  2004.  Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.. J Natl Cancer Inst. 96(11):834-43.

Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, Hofer MD, Storz-Schweizer M, Kuefer R, Fletcher JA et al..  2004.  Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer.. Cancer Res. 64(11):3814-22.

Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, Hofer MD, Storz-Schweizer M, Kuefer R, Fletcher JA et al..  2004.  Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer.. Cancer Res. 64(11):3814-22.

Browne T-J, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin MA.  2004.  Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens.. Hum Pathol. 35(12):1462-8.

Browne T-J, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin MA.  2004.  Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens.. Hum Pathol. 35(12):1462-8.

Rubin MA, Bismar TA, Andrén O, Mucci L, Kim R, Shen R, Ghosh D, Wei JT, Chinnaiyan AM, Adami H-O et al..  2005.  Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death.. Cancer Epidemiol Biomarkers Prev. 14(6):1424-32.

Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG et al..  2005.  Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.. Cancer Res. 65(13):5561-70.

Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG et al..  2005.  Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.. Cancer Res. 65(13):5561-70.

Hofer MD, Browne TJ, He L, Skotheim RI, Lothe RA, Rubin MA.  2005.  Identification of two molecular groups of seminomas by using expression and tissue microarrays.. Clin Cancer Res. 11(16):5722-9.

Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J et al..  2005.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.. Nature. 436(7047):117-22.

Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J et al..  2005.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.. Nature. 436(7047):117-22.

Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ et al..  2005.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.. Cancer Cell. 8(5):393-406.

Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, He L, Kutok J, Aster JC, Tang J, Kuefer R et al..  2006.  Defining aggressive prostate cancer using a 12-gene model.. Neoplasia. 8(1):59-68.

Demichelis F, Magni P, Piergiorgi P, Rubin MA, Bellazzi R.  2006.  A hierarchical Naïve Bayes Model for handling sample heterogeneity in classification problems: an application to tissue microarrays.. BMC Bioinformatics. 7:514.

Hofer MD, Kuefer R, Huang W, Li H, Bismar TA, Perner S, Hautmann RE, Sanda MG, Gschwend JE, Rubin MA.  2006.  Prognostic factors in lymph node-positive prostate cancer.. Urology. 67(5):1016-21.

Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera J-M, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG et al..  2006.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.. Cancer Res. 66(17):8337-41.

Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S, Tchinda J, Laxman B, Vessella RL, Beroukhim R et al..  2007.  Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.. Neoplasia. 9(3):200-6.

Mosquera J-M, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins C, Bismar TA et al..  2007.  Morphological features of TMPRSS2-ERG gene fusion prostate cancer.. J Pathol. 212(1):91-101.

Cohen RJ, Wheeler TM, Bonkhoff H, Rubin MA.  2007.  A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma.. Arch Pathol Lab Med. 131(7):1103-9.

Barry M, Perner S, Demichelis F, Rubin MA.  2007.  TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications.. Urology. 70(4):630-3.

Perner S, Mosquera J-M, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM et al..  2007.  TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.. Am J Surg Pathol. 31(6):882-8.

Mosquera J-M, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, Paris PL, Simko J, Bismar TA, Ayala G et al..  2008.  Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.. Clin Cancer Res. 14(11):3380-5.

Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, Moss BJ, Arbogast S, Soltermann A, Weder W, Giordano TJ et al..  2008.  EML4-ALK fusion lung cancer: a rare acquired event.. Neoplasia. 10(3):298-302.

Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA et al..  2008.  Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.. J Natl Cancer Inst. 100(11):815-25.